ReviewEmerging infectious diseases2025
Reemergence of Yellow Fever, Magdalena Valley, Colombia, 2024-2025.
Review in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Yellow fever virus infection in non-human primates: a systematic review and meta-analysis of prevalence, seroprevalence, and epizootic case reports (1950-2025).Frontiers in veterinary science · 2026Pooled it
- Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.New microbes and new infections · 2026Review
- Adverse Events Following Yellow Fever Vaccination in Older Adults in Colombia, 2024-2025: A National Pharmacovigilance Analysis.Vaccines · 2026Article
- Metagenomic Analysis Reveals Viral Diversity in Phlebotomine Sand Flies from Caribbean Region in Colombia.Microorganisms · 2026Article
- Revisiting the Status of Yellow Fever Epizootics and Its Surveillance in South America: New Non-Human Primates, Spillover and Ecological Drivers.Pathogens (Basel, Switzerland) · 2026Review
- Yellow fever in Latin America and the escalating risks in a changing eco-epidemiological landscape: a review.Lancet regional health. Americas · 2026Review
- Yellow fever among captive non-human primates in La Paz, Bolivia, 2025.New microbes and new infections · 2026Article
- Yellow fever re-emergence in Tolima, Colombia 2024-25: an eco-epidemiological study.medRxiv : the preprint server for health sciences · 2026Article
- Review
- Yellow fever in older adults: an overlooked high-risk population in South American outbreaks.Sustainable microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yellow fever, a zoonotic arboviral disease, has reemerged in Colombia, triggering a major outbreak in the country. During 2024 through mid-2025, a total of 132 human cases and 68 infections in nonhuman primates were confirmed, primarily in the department of Tolima, historically considered a low-risk area. We analyzed the historical and current epidemiology of yellow fever in Colombia, highlighting ecologic, social, and surveillance factors that contributed to the outbreak. Low vaccination coverage, insufficient epizootic and entomological surveillance, deforestation, habitat fragmentation, and limited application of One Health approaches have all exacerbated the situation. The high mortality rate of nonhuman primate species indicated a more profound ecologic crisis. Immediate, comprehensive measures, including mass vaccination, genomic surveillance, and integrated One Health frameworks, are urgently needed. Colombia's experience underscores the need to reevaluate risk stratification and preparedness strategies across the Americas to prevent future yellow fever outbreaks in previously unaffected regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.